Theranostic Nanomaterials to Overcome the Challenges in Peptide-based Cancer Therapy

Q2 Pharmacology, Toxicology and Pharmaceutics

Current Bioactive Compounds Pub Date : 2024-01-22 DOI:10.2174/0115734072285630240110115046

Saranya Selvaraj, Yasuri Amarasekara, Inoka C. Perera, L. Weerasinghe

{"title":"Theranostic Nanomaterials to Overcome the Challenges in Peptide-based\nCancer Therapy","authors":"Saranya Selvaraj, Yasuri Amarasekara, Inoka C. Perera, L. Weerasinghe","doi":"10.2174/0115734072285630240110115046","DOIUrl":null,"url":null,"abstract":"\n\nGlobally, the number of cancer cases and death rates are increasing, making it necessary to develop new and improved medications for the treatment of cancer.Owing to a broad\nrange of physio-chemical properties, Antimicrobial Peptides (AMPs) possessing tumoricidal\nproperties and Anticancer Peptides (ACPs) are promising alternatives for enhanced cancer therapy. Recently, biopharmaceuticals have changed the rules of radiation therapy and chemotherapy\nby introducing peptide therapy for cancer treatments. However, several limitations obstruct the\nclinical efficacy of peptide-based cancer therapies, which include limited target specificity, oral\nintake, and half-life payloads. The integration of theranostic nanomaterials could be facilitated as\na transformative strategy to address these challenges and enhance the potential of peptide-based\ncancer therapy. Increasing applications of recent times of peptide-nano hybrids have addressed\nthe crucial issues related to conventional peptide-based drug therapy by enhancing the druggability. This review aims to explore the impact of nano-formulated peptides as an anticancer agent,\nhighlighting the involvement of nanotechnology as an enabling tool.\n","PeriodicalId":10772,"journal":{"name":"Current Bioactive Compounds","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Bioactive Compounds","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115734072285630240110115046","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Globally, the number of cancer cases and death rates are increasing, making it necessary to develop new and improved medications for the treatment of cancer.Owing to a broad range of physio-chemical properties, Antimicrobial Peptides (AMPs) possessing tumoricidal properties and Anticancer Peptides (ACPs) are promising alternatives for enhanced cancer therapy. Recently, biopharmaceuticals have changed the rules of radiation therapy and chemotherapy by introducing peptide therapy for cancer treatments. However, several limitations obstruct the clinical efficacy of peptide-based cancer therapies, which include limited target specificity, oral intake, and half-life payloads. The integration of theranostic nanomaterials could be facilitated as a transformative strategy to address these challenges and enhance the potential of peptide-based cancer therapy. Increasing applications of recent times of peptide-nano hybrids have addressed the crucial issues related to conventional peptide-based drug therapy by enhancing the druggability. This review aims to explore the impact of nano-formulated peptides as an anticancer agent, highlighting the involvement of nanotechnology as an enabling tool.

查看原文本刊更多论文

克服基于肽的癌症疗法所面临挑战的抗癌纳米材料

在全球范围内，癌症病例数和死亡率都在不断上升，因此有必要开发新的改良药物来治疗癌症。由于具有广泛的物理化学特性，具有杀瘤特性的抗菌肽（AMPs）和抗癌肽（ACPs）是加强癌症治疗的有前途的替代品。最近，生物制药通过引入肽疗法治疗癌症，改变了放疗和化疗的规则。然而，基于肽的癌症疗法在临床疗效方面存在一些局限性，其中包括靶点特异性有限、口服摄入量和有效载荷的半衰期。治疗纳米材料的整合可作为一种变革性战略来应对这些挑战，并提高基于多肽的癌症疗法的潜力。近年来，肽纳米混合物的应用日益增多，通过提高可药性解决了与传统肽类药物治疗相关的关键问题。本综述旨在探讨纳米制剂肽作为抗癌剂的影响，强调纳米技术作为一种有利工具的参与。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Bioactive Compounds Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)

CiteScore

1.90

自引率

0.00%

发文量

112

期刊介绍： The journal aims to provide comprehensive review articles on new bioactive compounds with proven activities in various biological screenings and pharmacological models with a special emphasis on stereoeselective synthesis. The aim is to provide a valuable information source of bioactive compounds synthesized or isolated, which can be used for further development of pharmaceuticals by industry and academia. The journal should prove to be essential reading for pharmacologists, natural product chemists and medicinal chemists who wish to be kept informed and up-to-date with the most important developments on new bioactive compounds of natural or synthetic origin, including their stereoeselective synthesis.